September 22, 2026
The options market is doing the heavy analytical work for you
Markets don’t need good news to move a stock 12%. They only need a dated event to price in. On September 21, Moderna announced that three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted at the ESMO Congress 2026, held October 23-27 in Madrid.
61% of Americans Worry America Could be on the Verge of Another Civil War
Today, more than half of America thinks a civil war is likely.
Former CIA Advisor Jim Rickards agrees.
He just uncovered a fascinating plot by Trump to keep the Democrats out of the White House until 2033.
And while he believes it could be successful, it could also trigger America’s Second Civil War.
The crown jewel: the INTerpath-001 Phase 3 study earned a Presidential Symposium slot, scheduled for Saturday, October 24 at 4:30 PM CEST (10:30 AM EDT). MRNA closed at $172.94, up 12.27% on the session, a fresh 52-week high.
This is not about momentum. It is about what investors think they already know and what the data will confirm or destroy in 33 days.
What the Market Already Knows
Merck and Moderna announced positive topline results from INTerpath-001 on August 19, 2026, evaluating intismeran autogene in combination with Keytruda in patients with completely resected stage IIB-IV melanoma. The trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival. That was the first positive Phase 3 readout for an individualized neoantigen therapy. Detailed efficacy metrics, including hazard ratios, were not disclosed at that time; OS and other secondary endpoints remain immature.
The August 19 announcement was itself a market event worth examining in isolation, because the stock’s initial reaction to that topline — before any hazard ratios or survival curves were published — set the baseline from which the current 52-week high is measured. Understanding how the market priced incomplete information that day is directly relevant to how it may price the complete dataset on October 24. A closer look at how MRNA moved on the INTerpath-001 topline before any efficacy details were released shows just how much of the current premium was built on inference rather than confirmed numbers.
So the topline beat is confirmed. What ESMO delivers on October 24 is the full dataset: the hazard ratios, the subgroup breakdowns, the survival curves. No new efficacy data was released Monday; the Presidential Symposium slot itself is the signal, as organizers typically reserve it for potentially practice-changing datasets. The street is now paying a 12% premium to hold through the detailed presentation.
Marc Chaikin Issues the “Strangest” Prediction of His 60-Year Career
Wall Street legend Marc Chaikin has advised billionaires like George Soros, Steve Cohen and D.E. Shaw. He predicted the 2020 Covid Crash… the 2022 bear… and the 2025 tariff sell-off, too. But he’s never made a prediction like the one he just issued.
According to Chaikin, a $248T “White Swan” event is about to overturn the AI industry… and the global order, too. It involves a strange new technology called “micro clusters.” These miniaturized data centers will render current AI tech obsolete when it comes to major breakthroughs – including models from SpaceX, Google, Anthropic and OpenAI. And they could send shares of one obscure company soaring starting Sept. 29th.
Go here for Marc’s full prediction and the name and ticker of the stock, for free.
The Peer Read: Collaboration Is Not Consensus
Merck gained about 2% and BioNTech about 2% on September 21, signaling the market views this as a Moderna-specific re-rating, not a broad mRNA oncology validation. Merck is the pharma partner on intismeran autogene and supplies pembrolizumab, the checkpoint inhibitor combined with the vaccine in the study. BioNTech runs its own late-stage individualized mRNA cancer immunotherapy programs and traded higher on platform read-through, closing at $98.00, up about 2%. The asymmetry in those moves tells you where the binary exposure actually lives: in MRNA, not across the sector.
BioNTech’s muted reaction is partly a valuation story: the company runs its own late-stage individualized mRNA cancer programs but trades at a significant discount to Moderna on a per-platform basis, which limits both the upside read-through and the downside risk if ESMO data disappoints. That discount is not accidental — it reflects different pipeline timelines and commercial execution risk. Traders monitoring BNTX as a sentiment indicator may find it useful to review the case for BioNTech’s individualized mRNA cancer platform relative to Moderna’s current valuation before treating the two names as interchangeable proxies.
MRNA climbed from roughly $135.61 on September 9 to $172.94 on September 21, a gain of around 28% over that period as oncology and vaccine catalysts drew in momentum traders. Argus upgraded Moderna to Buy with a price target of $180, while Wolfe Research upgraded to Peer Perform, pointing to potential unadjusted peak sales of about $9.2 billion across multiple oncology indications.
Options Market Analysis
A near-30% move in under two weeks at a 52-week high with a hard-dated binary event 33 days out is precisely the environment where implied volatility compounds into the underlying premium. On September 21, share volume registered 21.02 million shares. With MRNA near a 52-week high and the October 24 symposium as a binary catalyst, front-month IV in the October expiration is commanding a premium to realized volatility from the past month.
The call/put skew matters here. When a stock is at a 52-week high and the Street has already priced in a known positive topline, call premium gets expensive in relative terms. The question for options positioning is not whether the drug works. The Phase 3 already answered that. The question is whether the detailed hazard ratios and survival curves exceed what the $172 stock price already reflects.
5 Little-Known Stocks Behind Today’s Defense Tech Shift
Behind the headlines, a major transformation is underway.
Modern warfare is being driven by AI, autonomous systems, and next generation technology. A handful of lesser known companies are helping power this shift.
This report uncovers five stocks quietly playing a critical role in the future of defense.
Structured Trade Framework
Bull case: If you believe the full ESMO data shows hazard ratios materially better than the Phase 2b KEYNOTE-942 benchmark (which demonstrated a 49% reduction in the risk of recurrence or death), a defined-risk long call spread targeting the $180-$200 range expiring in November captures the post-symposium move while capping the premium at risk. Avoid naked calls into a high-IV environment.
Bear case: For traders expecting a sell-the-news response after a near-30% run into the event, a defined-risk put spread below $155, expiring in late October, exploits elevated IV on the downside without unlimited exposure. The $22.28 fifty-two week low is a reminder of how violently this name can reprice.
Neutral case: An iron condor or short strangle structured around the October 24 event captures elevated IV from both sides, but requires precise wing placement. Given the stock’s capacity for 10%-plus single-session moves, wide wings and strict position sizing are non-negotiable.
Risk Analysis
The core risk is precisely what drove Monday’s rally: a conference slot is not data. ESMO Presidential Symposia tend to reserve their podium for potentially practice-changing results, but the full hazard ratios, confidence intervals, and secondary endpoint depth can still disappoint a market priced for a clean, regulatory-ready dataset. Detailed Phase 3 efficacy metrics were not disclosed in August, and overall survival and other secondary endpoints remain immature. If those endpoints disappoint, or the confidence intervals are wider than expected, the same momentum that drove MRNA higher will accelerate the reversal.
Action Checklist
- Confirm options expiration: target the October 30 or November expiry to capture the October 24 symposium readout with adequate time buffer.
- Check IV rank on any structure before entry. Elevated IV favors spreads over single-leg long options; standalone long calls are expensive at these levels.
- Track MRK and BNTX as real-time sentiment indicators. A divergence where MRNA continues higher while partners stall is a concentration risk flag.
- Set a predefined exit on any defined-risk structure: a 50% loss of premium paid is a disciplined stop for a binary event play.
- Mark the investor webcast: Moderna’s investor event is scheduled via webcast on Saturday, October 24 at 7:00 PM CEST / 1:00 PM EDT, immediately following the symposium presentation.
